Gamma Probe Device Market Size, Share, and Industry Analysis, By Product (Equipment and Accessories & Consumables), By Application (Sentinel Lymph Node Biopsy (SLNB), Tumor Localization, Parathyroid Surgery, and Others), By End-user (Hospitals & ASCs, Specialty Clinics, and Others), and Regional Forecast till 2034

The gamma probe device market size was valued at USD 218.2 million in 2025 and is expected to reach a market valuation of USD 231.6 million in 2026. Furthermore, the market is projected to reach a market valuation of USD 372.6 million by 2034, exhibiting a CAGR of 6.1% during the forecast period.

Currently, the healthcare facilities are shifting toward minimally invasive procedures. In such a scenario, gamma probes enable accurate intraoperative localization of diseased tissue, thereby reducing complications and improving outcomes. This is expected to increase their adoption, driving the market growth during the forecast period.

Gamma Probe Device Market Driver

Rising Incidence of Cancer to Drive the Market Growth

Over the past few years, there has been an increasing incidence of cancer, including breast cancer and melanoma, which has increased the number of sentinel lymph node biopsy (SLNB) procedures. In such surgeries, gamma probes play a vital role. As a result, higher cancer incidence is expected to drive demand for gamma probes, thereby augmenting the segment’s growth.

• For instance, according to data published by the Cancer Research Institute in February 2026, an estimated 2.1 million individuals are diagnosed with cancer in the U.S.

Download Free sample to learn more about this report.

According to data from the American Cancer Society, an estimated 2,114, 850 new cancer cases will be diagnosed in 2026.

Gamma Probe Device Market Restraint

Competition from Alternative Imaging & Localization Techniques to Hamper the Market Growth

Despite high demand for gamma probe devices, emerging alternatives such as fluorescence-guided surgery (ICG), magnetic tracers, and advanced imaging systems are gradually reducing reliance on traditional radioguided methods in certain procedures. Such a scenario is anticipated to hinder the market growth over the forecast period.

Gamma Probe Device Market Opportunity

Expansion in Emerging Markets to Offer Lucrative Growth Opportunity

In recent years, there has been an improvement in healthcare infrastructure and an increase in cancer diagnosis rates in emerging economies such as India, China, and Brazil. This is attracting key players to expand their product offerings in these countries, thereby driving significant market expansion.

• For instance, in 2023, the Indian Council of Medical Research (ICMR) reported over 1.4 million new cancer cases annually in India, with 60-70% diagnosed at an advanced stage.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence of Cancer, by Key Countries/Region, 2025
• Technological Advancements in Gamma Probe Devices
• Key Industry Developments - (Partnerships, Mergers, and Acquisitions, etc.)

Analysis by Product

By product, the market is segmented into equipment and accessories & consumables.

The equipment segment is expected to hold the major share of the global market during the forecast period. This growth is driven by ongoing technological advancements, such as wireless probes and improved detector sensitivity, which are driving replacement and upgrade cycles.

• For instance, a May 2021 study in the Journal of Nuclear Medicine described a tethered DROP-IN gamma probe, applied for both sentinel lymph node (SLN) biopsy and PSMA-targeted salvage radioguidance.

Analysis by Application

By application, the market is segmented into sentinel lymph node biopsy (SLNB), tumor localization, parathyroid surgery, and others.

The sentinel lymph node biopsy (SLNB) segment is expected to hold the major share of the global market during the forecast period. This growth is attributed to the high global incidence of breast cancer, which significantly drives procedural volumes, directly translating into higher device utilization.

• For instance, according to the data published by the American Cancer Society in July 2024, about 1 in 8 women (13.1%) were projected to develop invasive breast cancer in the U.S.

Analysis by End-user

Based on end-user, the market is divided into hospitals & ASCs, specialty clinics, and others.

The hospitals & ASCs segment is expected to hold the largest share of the global market during the forecast period. Most SLNB, tumor localization, and parathyroid surgeries are performed in hospital settings due to the need for advanced surgical infrastructure, radiotracer handling capabilities, and multidisciplinary teams. This is expected to drive the adoption of gamma probes in these settings, contributing to the segment’s growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a 41.8% share of the global gamma probe device market in 2025. The growth is attributed to strong adoption of radioguided surgery workflows, supported by the region's established healthcare infrastructure. Also, the strong presence of major players in the region is expected to support product adoption and drive the region’s growth.

Asia Pacific is expected to grow at the highest CAGR during the forecast period. The growth is attributed to the large patient pool of breast cancer and melanoma in the region, which is influencing key players to expand their offerings and footprint in countries such as India, China, and South Korea.

• For instance, the World Cancer Research Fund stated that there were 192,020 incident cases of breast cancer in India in 2022.

Key Players Covered

The global gamma probe market remains highly fragmented, with leading companies launching innovative products and increasing R&D investments.

The report includes the profiles of the following key players:

• Mammotome (U.S.)
• Hologic, Inc. (U.S.)
• Dilon Technologies (U.S.)
• LabLogic Systems Ltd (U.K.)
• Gamma Medical Technology (U.S.)
• KUBTEC (U.S.)
• Avicenna Instruments (France)
• Intramedical Imaging, LLC (U.S.)
• Crystal Photonics GmbH (Germany)
• CLERAD (France)

Key Industry Developments

• March 2024: Lightpoint Medical achieved a world first by using its SENSEI Drop-In gamma probe in bladder cancer surgery at Hospital del Mar, Barcelona, enabling sentinel lymph node (SLN) detection during robotic-assisted cystectomy.
• October 2021: Lightpoint Medical announced positive interim results from a multi-center trial showing its SENSEI miniature gamma probe achieved 100% sentinel lymph node detection in prostate cancer surgery, outperforming rigid probes.